FX006: Phase IIb resumed

Flexion resumed a double-blind, placebo-controlled, U.S. Phase IIb trial of FX006 after FDA lifted a clinical hold on the product. The trial had enrolled about 150 patients at the time of the hold and is evaluating single intra-articular injections of 20 and 40 mg FX006 in about 300 patients with OA of the knee. ...